Spedra

Country: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Vara einkenni Vara einkenni (SPC)
24-11-2021
Opinber matsskýrsla Opinber matsskýrsla (PAR)
10-03-2015

Virkt innihaldsefni:

avanafil

Fáanlegur frá:

Menarini International Operations Luxembourg S.A.

ATC númer:

G04BE10

INN (Alþjóðlegt nafn):

avanafil

Meðferðarhópur:

Drugs used in erectile dysfunction

Lækningarsvæði:

Erectile Dysfunction

Ábendingar:

Treatment of erectile dysfunction in adult men.In order for Spedra to be effective, sexual stimulation is required.

Vörulýsing:

Revision: 13

Leyfisstaða:

Authorised

Leyfisdagur:

2013-06-21

Upplýsingar fylgiseðill

                                54
B. PACKAGE LEAFLET
55
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
SPEDRA 50 MG TABLETS
avanafil
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Spedra is and what it is used for
2.
What you need to know before you take Spedra
3.
How to take Spedra
4.
Possible side effects
5.
How to store Spedra
6.
Contents of the pack and other information
1.
WHAT SPEDRA IS AND WHAT IT IS USED FOR
Spedra contains the active substance avanafil. It belongs to a group
of medicines called
phosphodiesterase type 5 (PDE5) inhibitors. Spedra is a treatment for
adult men suffering from
erectile dysfunction (also known as impotence). This is when you
cannot get, or keep a hard, erect
penis suitable for sexual activity.
Spedra works by helping the blood vessels in your penis to relax. This
increases the blood flow into
your penis, helping it stay hard and erect when you get sexually
excited. Spedra does not cure your
condition.
It is important to note that Spedra only works if you are sexually
stimulated. You and your partner will
still need to use foreplay to get ready for sex – just as you would
if you were not taking a medicine to
help you.
Spedra will not help you if you do not have erectile dysfunction.
Spedra is not for women.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE SPEDRA
DO NOT TAKE SPEDRA:
•
If you are allergic to avanafil or any of the other ingredients of
this medicine (listed in section 6)
•
If you are taking “nitrate” medicines for chest pain (angina),
such as amyl nitrite or glyceryl
trinitrat
                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Spedra 50 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 mg of avanafil.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Pale yellow oval tablets, debossed with “50” on one side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of erectile dysfunction in adult men.
In order for Spedra to be effective, sexual stimulation is required.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Use in adult men _
The recommended dose is 100 mg taken as needed approximately 15 to 30
minutes before sexual
activity (see section 5.1). Based on individual efficacy and
tolerability, the dose may be increased to a
maximum dose of 200 mg or decreased to 50 mg. The maximum recommended
dosing frequency is
once per day. Sexual stimulation is required for a response to
treatment.
_Special populations _
_Elderly(≥ 65 years old) _
Dose adjustments are not required in elder patients. Limited data are
available in elder patients aged
70 years or above.
_Renal impairment _
Dose adjustments are not required in patients with mild to moderate
renal impairment (creatinine
clearance ≥ 30 mL/min). Spedra is contraindicated in patients with
severe renal impairment (creatinine
clearance < 30 mL/min) (see sections 4.3 and 5.2). Patients with mild
or moderate renal impairment
(creatinine clearance ≥30 mL/min but <80 mL/min) who were enrolled
in phase 3 studies showed
decreased efficacy compared to those with normal renal function.
_Hepatic impairment _
Spedra is contraindicated in patients with severe hepatic impairment
(Child Pugh class C) (see
sections 4.3 and 5.2). Patients with mild to moderate hepatic
impairment (Child-Pugh class A or B)
should initiate treatment with the minimum efficacious dose and adjust
posology based on tolerance.
_Use in men with diabetes _
Dose adjustments are not required in diabetic patients.
3
_Paediatric population _
There is no relevant use of Spedra i
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 24-11-2021
Vara einkenni Vara einkenni búlgarska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla búlgarska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 24-11-2021
Vara einkenni Vara einkenni spænska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla spænska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 24-11-2021
Vara einkenni Vara einkenni tékkneska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla tékkneska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 24-11-2021
Vara einkenni Vara einkenni danska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla danska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 24-11-2021
Vara einkenni Vara einkenni þýska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla þýska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 24-11-2021
Vara einkenni Vara einkenni eistneska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla eistneska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 24-11-2021
Vara einkenni Vara einkenni gríska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla gríska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 24-11-2021
Vara einkenni Vara einkenni franska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla franska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 24-11-2021
Vara einkenni Vara einkenni ítalska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla ítalska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 24-11-2021
Vara einkenni Vara einkenni lettneska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla lettneska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 24-11-2021
Vara einkenni Vara einkenni litháíska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla litháíska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 24-11-2021
Vara einkenni Vara einkenni ungverska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla ungverska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 24-11-2021
Vara einkenni Vara einkenni maltneska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla maltneska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 24-11-2021
Vara einkenni Vara einkenni hollenska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla hollenska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 24-11-2021
Vara einkenni Vara einkenni pólska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla pólska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 24-11-2021
Vara einkenni Vara einkenni portúgalska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla portúgalska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 24-11-2021
Vara einkenni Vara einkenni rúmenska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla rúmenska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 24-11-2021
Vara einkenni Vara einkenni slóvakíska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 24-11-2021
Vara einkenni Vara einkenni slóvenska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla slóvenska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 24-11-2021
Vara einkenni Vara einkenni finnska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla finnska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 24-11-2021
Vara einkenni Vara einkenni sænska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla sænska 10-03-2015
Upplýsingar fylgiseðill Upplýsingar fylgiseðill norska 24-11-2021
Vara einkenni Vara einkenni norska 24-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill íslenska 24-11-2021
Vara einkenni Vara einkenni íslenska 24-11-2021
Upplýsingar fylgiseðill Upplýsingar fylgiseðill króatíska 24-11-2021
Vara einkenni Vara einkenni króatíska 24-11-2021
Opinber matsskýrsla Opinber matsskýrsla króatíska 10-03-2015

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu